Design, synthesis, and biological evaluation of indenoisoquinoline rexinoids with chemopreventive potential

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2581-2605

  Conda Sheridan, Martin ^a   Park, Eun Jung ^c   Beck, Daniel E ^a   Reddy, P V Narasimha ^a   Nguyen, Trung X ^a   Hu, Bingjie ^a   Chen, Lian ^b   White, Jerry J ^b   Van Breemen, Richard B ^b   Pezzuto, John M ^c   Cushman, Mark ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACETIC ACID; 3 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACRYLIC ACID; 3 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACRYLONITRILE; 3 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)PROPIOLIC ACID; 3 BROMO 6 METHYL 5H INDENO[1,2 C]ISOQUINOLINE 5,11(6H)DIONE; 3 CHLORO 6 METHYL 5H INDENO[1,2 C]ISOQUINOLINE 5,11(6H)DIONE; 3 CYANO 5,11 DIHYDRO 6 METHYL 5,11 DIOXOINDENO[1,2 C]ISOQUINOLINE; 3 IODO 6 METHYL 5H INDENO[1,2 C]ISOQUINOLINE 5,11(6H) DIONE; 3,6 DIMETHYL 5H INDENO[1,2 C]ISOQUINOLINE 5,11(6H)DIONE; 5 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)BUTANOIC ACID; 5 METHYLHOMOPHTHALIC ANHYDRIDE; 6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBALDEHYDE; 6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBOXAMIDE; 6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; CARBOXYL GROUP; ETHYL 1 BROMO 3 OXO 1,3 DIHYDROISOBENZOFURAN 5 CARBOXYLATE; ETHYL 1 HYDROXY 3 OXO 1,3 DIHYDROISOBENZOFURAN 5 CARBOXYLATE; ETHYL 2 CYANO 2 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACETATE; INDENOISOQUINOLINE REXINOID; METHYL 2 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACETATE; METHYL 3 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)ACRYLATE; METHYL 3 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)PROPIOLATE; METHYL 5 (6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLIN 3 YL)BUTANOATE; METHYL 5,11 DIOXO 5,11 DIHYDROINDENO[1,2 C]ISOCHROMENE 3 CARBOXYLATE; METHYL 6 [3 (1H IMIDAZOL 1 YL)PROPYL] 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBOXYLATE HYDROCHLORIDE; METHYL 6 [3 [(TERT BUTOXYCARBONYL)AMINO]PROPYL] 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBOXYLATE; METHYL 6 METHYL 5,11 DIOXO 6,11 DIHYDRO 5H INDENO[1,2 C]ISOQUINOLINE 3 CARBOXYLATE; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG DESIGN; DRUG SCREENING; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTICARCINOGENIC AGENTS; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; HUMANS; ISOQUINOLINES; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; RECEPTORS, CALCITRIOL; RETINOID X RECEPTOR ALPHA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875712796     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400026k     Document Type: Article

References (75)

1. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The Nuclear Receptor Superfamily: The Second Decade Cell 1995, 83, 835-839
2. Evans, R. M. The Steroid and Thyroid Hormone Receptor Superfamily Science 1988, 240, 889-895
3. Robinson-Rechavi, M.; Carpentier, A. S.; Duffraisse, M.; Laudet, V. How Many Nuclear Hormone Receptors Are There in the Human Genome? Trends Genet. 2001, 17, 554-556
4. Robinson-Rechavi, M.; Escriva Garcia, H.; Laudet, V. The Nuclear Receptor Superfamily J. Cell Sci. 2003, 116, 585-586
5. Bertrand, S.; Brunet, F. G.; Escriva Garcia, H.; Parmentier, G.; Laudet, V.; Robinson-Rechavi, M. Evolutionary Genomics of Nuclear Receptors: From Twenty-Five Ancestral Genes to Derived Endocrine Systems Mol. Biol. Evol. 2004, 21, 1923-1937
6. Olefsky, J. M. Nuclear Receptor Minireview Series J. Biol. Chem. 2001, 276, 36863-36864
7. Wagner, C. E.; Jurutka, P. W.; Marshall, P. A.; Groy, T. L.; van der Vaart, A.; Ziller, J. W.; Furmick, J. K.; Graeber, M. E.; Matro, E.; Miguel, B. V.; Tran, I. T.; Kwon, J.; Tedeschi, J. N.; Moosavi, S.; Danishyar, A.; Philp, J. S.; Khamees, R. O.; Jackson, J. N.; Grupe, D. K.; Badshah, S. L.; Hart, J. W. Modeling, Synthesis and Biological Evaluation of Potential Retinoid X Receptor (RXR) Selective Agonists: Novel Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7, 8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) J. Med. Chem. 2009, 52, 5950-5966
8. Chen, Z. P.; Iyer, J.; Bourguet, W.; Held, P.; Mioskowski, C.; Lebeau, L.; Noy, N.; Chambon, P.; Gronemeyer, H. Ligand- and DNA-Induced Dissociation of RXR Tetramers J. Mol. Biol. 1998, 275, 55-65
9. Shulman, A. I.; Larson, C.; Mangelsdorf, D. J.; Ranganathan, R. Structural Determinants of Allosteric Ligand Activation in RXR Heterodimers Cell 2004, 116, 417-429
10. Hamada, K.; Gleason, S. L.; Levi, B. Z.; Hirschfeld, S.; Appella, E.; Ozato, K. H-2RIIBP, a Member of the Nuclear Hormone Receptor Superfamily that Binds to Both the Regulatory Element of Major Histocompatibility Class I Genes and the Estrogen Response Element Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 8289-8293
11. Dolle, P.; Fraulob, V.; Kastner, P.; Chambon, P. Developmental Expression of Murine Retinoid X Receptor (RXR) Genes Mech. Dev. 1994, 45, 91-104
12. Mangelsdorf, D. J.; Borgmeyer, U.; Heyman, R. A.; Zhou, J. Y.; Ong, E. S.; Oro, A. E.; Kakizuka, A.; Evans, R. M. Characterization of Three RXR Genes That Mediate the Action of 9- cis -Retinoic Acid Genes Dev. 1992, 6, 329-344
13. Mangelsdorf, D. J.; Ong, E. S.; Dyck, J. A.; Evans, R. M. Nuclear Receptor That Identifies a Novel Retinoic Acid Response Pathway Nature 1990, 345, 224-229
14. Nagpal, S.; Chandraratna, R. Retinoids as Anti-Cancer Agents Curr. Pharm. Des. 1996, 2, 295-316
15. Germain, P.; Chambon, P.; Eichele, G.; Evans, R. M.; Lazar, M. A.; Leid, M.; De Lera, A. R.; Lotan, R.; Mangelsdorf, D. J.; Gronemeyer, H. International Union of Pharmacology. LXIII. Retinoid X Receptors Pharmacol. Rev. 2006, 58, 760-772
16. Lotan, R. Retinoids in Cancer Chemoprevention FASEB J. 1996, 10, 1031-1039
17. Lotan, R. Retinoids and Apoptosis: Implications for Cancer Chemoprevention and Therapy J. Natl. Cancer Inst. 1995, 87, 1655-1657
18. Tanaka, T.; De Luca, L. M. Therapeutic Potential of "Rexinoids" in Cancer Prevention and Treatment Cancer Res. 2009, 69, 4945-4947
19. Bollag, W.; Holdener, E. E. Retinoids in Cancer Prevention and Therapy Ann. Oncol. 1992, 3, 513-526
20. Bollag, W.; Hartmann, H. R. Prevention and Therapy of Cancer with Retinoids in Animals and Man Cancer Surv. 1983, 2, 293-314
21. Alvarez, R. D.; Conner, M. G.; Weiss, H.; Klug, P. M.; Niwas, S.; Manne, U.; Bacus, J.; Kagan, V.; Sexton, K. C.; Grubbs, C. J.; Eltoum, I. E.; Grizzle, W. E. The Efficacy of 9- cis -Retinoic Acid (Aliretinoin) as a Chemopreventive Agent for Cervical Dysplasia: Results of a Randomized Double-Blind Clinical Trial Cancer Epidemiol., Biomarkers Prev. 2003, 12, 114-119
22. Zusi, F. C.; Lorenzi, M. V.; Vivat-Hannah, V. Selective Retinoids and Rexinoids in Cancer Therapy and Chemoprevention Drug Discovery Today 2002, 7, 1165-1174
23. Ruzicka, T.; Lynde, C. W.; Jemec, G. B.; Diepgen, T.; Berth-Jones, J.; Coenraads, P. J.; Kaszuba, A.; Bissonnette, R.; Varjonen, E.; Hollo, P.; Cambazard, F.; Lahfa, M.; Elsner, P.; Nyberg, F.; Svensson, A.; Brown, T. C.; Harsch, M.; Maares, J. Efficacy and Safety of Oral Alitretinoin (9- cis -Retinoic Acid) in Patients with Severe Chronic Hand Eczema Refractory to Topical Corticosteroids: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicentre Trial Br. J. Dermatol. 2008, 158, 808-817
24. Ponthan, F.; Kogner, P.; Bjellerup, P.; Klevenvall, L.; Hassan, M. Bioavailability and Dose-Dependent Anti-Tumour Effects of 9- cis -Retinoic Acid on Human Neuroblastoma Xenografts in Rat Br. J. Cancer 2001, 85, 2004-2009
25. David, M.; Hodak, E.; Lowe, N. J. Adverse-Effects of Retinoids Med. Toxicol. Adverse Drug Exper. 1988, 3, 273-288
26. Qu, L. Y.; Tang, X. W. Bexarotene: A Promising Anticancer Agent Cancer Chemother. Pharmacol. 2010, 65, 201-205
27. Gniadecki, R.; Assaf, C.; Bagot, M.; Dummer, R.; Duvic, M.; Knobler, R.; Ranki, A.; Schwandt, P.; Whittaker, S. The Optimal Use of Bexarotene in Cutaneous T-Cell Lymphoma Br. J. Dermatol. 2007, 157, 433-440
28. Brown, P.; Arun, B.; Miller, A.; Isaacs, C.; Gutierrez, C.; Huang, J.; Mohsin, S.; Sneige, N.; Kim, H.; Sexton, K.; Weiss, H.; Hilsenbeck, S.; Lamph, W.; Negro-Vilar, A.; Johnson, K.; Elledge, R. Prevention of Breast Cancer Using Rexinoids: Results of a Phase II Biomarker Modulation Trial Using Bexarotene in Women at High Risk of Breast Cancer Breast Cancer Res. Treat. 2007, 106, S181-S182
29. Esteva, F. J.; Glaspy, J.; Baidas, S.; Laufman, L.; Hutchins, L.; Dickler, M.; Tripathy, D.; Cohen, R.; DeMichele, A.; Yocum, R. C.; Osborne, C. K.; Hayes, D. F.; Hortobagyi, G. N.; Winer, E.; Demetri, G. D. Multicenter Phase II Study of Oral Bexarotene for Patients with Metastatic Breast Cancer J. Clin. Oncol. 2003, 21, 999-1006
30. Dawson, M. I.; Xia, Z. B. The Retinoid X Receptors and Their Ligands Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2012, 1821, 21-56
31. Ohsawa, F.; Morishita, K.; Yamada, S.; Makishima, M.; Kakuta, H. Modification at the Lipophilic Domain of RXR Agonists Differentially Influences Activation of RXR Heterodimers ACS Med. Chem. Lett. 2010, 1, 521-525
32. Liby, K. T.; Yore, M. M.; Sporn, M. B. Triterpenoids and Rexinoids as Multifunctional Agents for the Prevention and Treatment of Cancer Nat. Rev. Cancer 2007, 7, 357-369
33. (WAF1/CIP1) by Indenoisoquinolines in MCF7 Cells Cancer Prev. Res. 2011, 4, 592-607
34. Todorovic, N.; Awuah, E.; Albu, S.; Ozimok, C.; Capretta, A. Synthesis of Substituted Isoquinolines via Pd-Catalyzed Cross-Coupling Approaches Org. Lett. 2011, 13, 6180-6183
35. Ohta, C.; Kuwabe, S.; Shiraishi, T.; Shinohara, I.; Araki, H.; Sakuyama, S.; Makihara, T.; Kawanaka, Y.; Ohuchida, S.; Seko, T. An Improved Synthesis of the Selective EP4 Receptor Agonist ONO-4819 J. Org. Chem. 2009, 74, 8298-8308
36. Kang, D. W.; Kim, Y. S.; Lim, K. S.; Kim, M. S.; Pearce, L. V.; Pavlyukovets, V. A.; Tao, A. K.; Lang-Kuhs, K. A.; Blumberg, P. M.; Lee, J. Halogenation of 4-Hydroxy/amino-3-methoxyphenyl Acetamide TRPV1 Agonists Showed Enhanced Antagonism to Capsaicin Bioorg. Med. Chem. 2010, 18, 8092-8105
37. Egbertson, M. S.; Naylor, A. M.; Hartman, G. D.; Cook, J. J.; Gould, R. J.; Holahan, M. A.; Lynch, J. J.; Lynch, R. J.; Stranieri, M. T.; Vassallo, L. M. Nonpeptide Fibrinogen Receptor Antagonists. III. Design and Discovery of a Centrally Constrained Inhibitor Bioorg. Med. Chem. Lett. 1994, 4, 1835-1840
38. Meca, L.; Cisarova, I.; Drahonovsky, D.; Dvorak, D. Enantiomerically Pure Axially Chiral Aminocarbene Complexes of Chromium Organometallics 2008, 27, 1850-1858
39. Anzalone, L.; Hirsch, J. A. Substituent Effects on Hydrogenation of Aromatic Rings-Hydrogenation vs Hydrogenolysis in Cyclic Analogs of Benzyl Ethers J. Org. Chem. 1985, 50, 2128-2133
40. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. Synthesis of Benz[ d ]indeno[1,2- b ]pyran-5,11-diones: Versatile Intermediates for the Design and Synthesis of Topoisomerase I Inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 1846-1849
41. Kang, S. U.; Yang, G.; Li, W.; Zhang, Z. Y.; Burke, T. R. Enantioselective Synthesis of (S)-3-Carboxy-4-((carboxy)difluoromethyl) phenylalanine in Protected Form and Its Incorporation Into a PTP-1B-Directed Tripeptide Chem. Biodiversity 2004, 1, 626-633
42. Rydon, H. N.; Undheim, K. Polyazanaphthalenes. IX. Synthesis of Some Folic Acid Antagonists J. Chem. Soc. 1962, 4689-4695
43. Conda-Sheridan, M.; Reddy, P. V. N.; Morrell, A.; Cobb, B. T.; Marchand, C.; Agama, K.; Chergui, A.; Renaud, A.; Stephen, A. G.; Bindu, L. K.; Pommier, Y.; Cushman, M. Synthesis and Biological Evaluation of Indenoisoquinolines that Inhibit both Tyrosyl-DNA-Phosphodiesterase I (Tdp1) and Topoisomerase I (Top1) J. Med. Chem. 2013, 56, 182-200
44. Chen, L.; Conda-Sheridan, M.; Reddy, P. V.; Morrell, A.; Park, E. J.; Kondratyuk, T. P.; Pezzuto, J. M.; van Breemen, R. B.; Cushman, M. Identification, Synthesis, and Biological Evaluation of the Metabolites of 3-Amino-6-(3′-aminopropyl)-5 H -indeno[1,2- c ]isoquinoline-5,11-(6 H)dione (AM6-36), a Promising Rexinoid Lead Compound for the Development of Cancer Chemotherapeutic and Chemopreventive Agents J. Med. Chem. 2012, 55, 5965-5981
45. Fujii, S.; Ohsawa, F.; Yamada, S.; Shinozaki, R.; Fukai, R.; Makishima, M.; Enomoto, S.; Tai, A.; Kakuta, H. Modification at the Acidic Domain of RXR Agonists Has Little Effect on Permissive RXR-Heterodimer Activation Bioorg. Med. Chem. Lett. 2010, 20, 5139-5142
46. Zhang, H. T.; Li, L.; Chen, L. L.; Hu, L. H.; Jiang, H. L.; Shen, X. Structure Basis of Bigelovin as a Selective RXR Agonist with a Distinct Binding Mode J. Mol. Biol. 2011, 407, 13-20
47. Kotani, H.; Tanabe, H.; Mizukami, H.; Makishima, M.; Inoue, M. Identification of a Naturally Occurring Rexinoid, Honokiol, That Activates the Retinoid X Receptor J. Nat. Prod. 2010, 73, 1332-1336
48. Zhang, H. T.; Xu, X.; Chen, L. L.; Chen, J.; Hu, L. H.; Jiang, H. L.; Shen, X. Molecular Determinants of Magnolol Targeting Both RXRα and PPARγ PLoS One 2011, 6, e28523
49. Nguyen, T. X.; Morrell, A.; Conda-Sheridan, M.; Marchand, C.; Agama, K.; Bermingam, A.; Stephen, A. G.; Chergui, A.; Naumova, A.; Fisher, R.; O'Keefe, B. R.; Pommier, Y.; Cushman, M. Synthesis and Biological Evaluation of the First Dual Tyrosyl-DNA Phosphodiesterase I (Tdp1)-Topoisomerase I (Top1) Inhibitors J. Med. Chem. 2012, 55, 4457-4478
50. Wang, W.; Cha, X. X.; Reiner, J.; Gao, Y.; Qiao, H. L.; Shen, J. X.; Chang, J. B. Synthesis and Biological Activity of n -Butylphthalide Derivatives Eur. J. Med. Chem. 2010, 45, 1941-1946
51. http://www.molinspiration.com/cgi-bin/properties (accessed July 23, 2012).
52. http://aceorganic.pearsoncmg.com/epoch-plugin/public/pKa.jsp (accessed July 23, 2012).
53. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved Protein-Ligand Docking Using GOLD Proteins: Struct., Funct., Genet. 2003, 52, 609-623
54. Zhou, Z. Y.; Felts, A. K.; Friesner, R. A.; Levy, R. M. Comparative Performance of Several Flexible Docking Programs and Scoring Functions: Enrichment Studies for a Diverse Set of Pharmaceutically Relevant Targets J. Chem. Inf. Model. 2007, 47, 1599-1608
55. Cross, J. B.; Thompson, D. C.; Rai, B. K.; Baber, J. C.; Fan, K. Y.; Hu, Y. B.; Humblet, C. Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy J. Chem. Inf. Model. 2009, 49, 1455-1474
56. Cummings, M. D.; DesJarlais, R. L.; Gibbs, A. C.; Mohan, V.; Jaeger, E. P. Comparison of Automated Docking Programs as Virtual Screening Tools J. Med. Chem. 2005, 48, 962-976
57. Trott, O.; Olson, A. J. AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading J. Comput. Chem. 2010, 31, 455-461
58. Dominguez, B.; Vega, M. J.; Sussman, F.; de Lera, A. R. Synthesis and Characterization of a New RXR Agonist Based on the 6- tert -Butyl-1,1- dimethylindanyl Structure Bioorg. Med. Chem. Lett. 2002, 12, 2607-2609
59. Alvarez, R. D.; Vega, M. J.; Kammerer, S.; Rossin, A.; Germain, P.; Gronemeyer, H.; de Lera, A. R. 9- cis -Retinoic Acid Analogues with Bulky Hydrophobic Rings: New RXR-Selective Agonists Bioorg. Med. Chem. Lett. 2004, 14, 6117-6122
60. Sussman, F.; de Lera, A. R. Ligand Recognition by RAR and RXR Receptors: Binding and Selectivity J. Med. Chem. 2005, 48, 6212-6219
61. Takamatsu, K.; Takano, A.; Yakushiji, N.; Morishita, K.; Matsuura, N.; Makishima, M.; Ali, H. I.; Akaho, E.; Tai, A.; Sasaki, K.; Kakuta, H. Reduction of Lipophilicity at the Lipophilic Domain of RXR Agonists Enables Production of Subtype Preference: RXR Molecular Determinants of Magnolol Targeting Both RXRα-Preferential Agonist Possessing a Sulfonamide Moiety ChemMedChem 2008, 3, 454-460
62. Gampe, R. T.; Montana, V. G.; Lambert, M. H.; Wisely, G. B.; Milburn, M. V.; Xu, H. E. Structural Basis for Autorepression of Retinoid X Receptor by Tetramer Formation and the AF-2 Helix Genes Dev. 2000, 14, 2229-2241
63. Cesario, R. M.; Klausing, K.; Razzaghi, H.; Crombie, D.; Rungta, D.; Heyman, R. A.; Lala, D. S. The Rexinoid LG100754 is a Novel RXR: PPAR Gamma Agonist and Decreases Glucose Levels in Vivo Mol. Endocrinol. 2001, 15, 1360-1369
64. Szanto, A.; Narkar, V.; Shen, Q.; Uray, I. P.; Davies, P. J.; Nagy, L. Retinoid X Receptors: X-ploring Their (Patho)Physiological Functions Cell Death Differ. 2004, 11 (Suppl. 2) S126-S143
65. de Lera, A. R.; Bourguet, W.; Altucci, L.; Gronemeyer, H. Design of Selective Nuclear Receptor Modulators: RAR and RXR as a Case Study Nat. Rev. Drug Discovery 2007, 6, 811-820
66. Liu, D.; Guo, J.; Luo, Y.; Broderick, D. J.; Schimerlik, M. I.; Pezzuto, J. M.; van Breemen, R. B. Screening for Ligands of Human Retinoid X Receptor-alpha Using Ultrafiltration Mass Spectrometry Anal. Chem. 2007, 79, 9398-9402
67. Liu, S.; Ogilvie, K. M.; Klausing, K.; Lawson, M. A.; Jolley, D.; Li, D. M.; Bilakovics, J.; Pascual, B.; Hein, N.; Urcan, M.; Leibowitz, M. D. Mechanism of Selective Retinoid X Receptor Agonist-Induced Hypothyroidism in the Rat Endocrinology 2002, 143, 2880-2885
68. Thompson, P. D.; Jurutka, P. W.; Haussler, C. A.; Whitfield, G. K.; Haussler, M. R. Heterodimeric DNA Binding by the Vitamin D Receptor and Retinoid X Receptors Is Enhanced by 1,25-Dihydroxyvitamin D3 and Inhibited by 9- cis -Retinoic Acid. Evidence for Allosteric Receptor Interactions J. Biol. Chem. 1998, 273, 8483-8491
69. Li, X. Y.; Xiao, J. H.; Feng, X.; Qin, L.; Voorhees, J. J. Retinoid X Receptor-Specific Ligands Synergistically Upregulate 1,25-dihydroxyvitamin D3-Dependent Transcription in Epidermal Keratinocytes in Vitro and in Vivo J. Invest. Dermatol. 1997, 108, 506-512
70. Bartik, L.; Whitfield, G. K.; Kaczmarska, M.; Lowmiller, C. L.; Moffet, E. W.; Furmick, J. K.; Hernandez, Z.; Haussler, C. A.; Haussler, M. R.; Jurutka, P. W. Curcumin: A Novel Nutritionally Derived Ligand of the Vitamin D Receptor with Implications for Colon Cancer Chemoprevention J. Nutr. Biochem. 2010, 21, 1153-1161
71. Wilson, G. L.; Lill, M. A. Integrating Structure-Based and Ligand-Based Approaches for Computational Drug Design Future Med. Chem. 2011, 3, 735-750
72. DeLano, W. L. The PyMOL Molecular Graphics System: DeLano Scientific: San Carlos, CA, U.S., 2002.
73. Egea, P. F.; Mitschler, A.; Moras, D. Molecular Recognition of Agonist Ligands by RXRs Mol. Endocrinol. 2002, 16, 987-997
74. Bejugam, M.; Gunaratnam, M.; Muller, S.; Sanders, D. A.; Sewitz, S.; Fletcher, J. A.; Neidle, S.; Balasubramanian, S. Targeting the c -Kit Promoter G-quadruplexes with 6-Substituted Indenoisoquinolines ACS Med. Chem. Lett. 2010, 1, 306-310
75. Wawzonek, S. Synthesis of 6-Substituted-6 H -indeno[1,2- c ]isoquinoline-5,11-diones Org. Prep. Proced. Int. 1982, 14, 163-168